Osimertinib after Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and Post-progression Outcomes from the Phase III LAURA Study
Year: 2026
Type: article
Abstract: INTRODUCTION: In the phase III LAURA study, osimertinib demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) without disease progression during/after chemoradiotherapy. We report pre-specified post-progression outcomes, subsequent treatments and a second interim analysis of overall survival (OS). METHODS: Patients were randomized 2:1 to receive osimertinib or placebo until progression (blinded independent central review) or discontinuation. Open-label osimertinib was offered post-progression. Secondary endpoints included time to first and second subsequent treatment (TFST and TSST), second PFS (PFS2) and OS. RESULTS: At primary data cutoff (January 5, 2024), TFST (hazard ratio [HR], 0.13; 95% CI, 0.08-0.21), PFS2 (0.62; 0.35-1.08) and TSST (0.51; 0.28-0.91) were improved with osimertinib versus placebo. As reported previously, 63/143 (44%) and 66/73 (90%) patients had discontinued randomized osimertinib and placebo treatment, respectively. The most common first subsequent systemic treatment was an EGFR-tyrosine kinase inhibitor in the osimertinib and placebo arms (22/63 [35%] and 56/66 [85%], respectively), primarily osimertinib (14/63 [22%] and 50/66 [76%]). At the second interim OS analysis (data cutoff: November 29, 2024), there was a trend towards OS benefit with osimertinib versus placebo (HR, 0.67; 95% CI, 0.40-1.14; 31% maturity). CONCLUSIONS: Osimertinib demonstrated clinically meaningful improvements versus placebo in TFST, PFS2 and TSST, and a trend towards OS benefit. These data indicate that clinical benefit with osimertinib was preserved beyond first progression, supporting long-term benefits of osimertinib for unresectable stage III EGFR-mutated NSCLC without progression during/after definitive chemoradiotherapy.
Source: Clinical Cancer Research
Authors: Mustafa Özgüroğlu, Myung-Ju Ahn, Xiaorong Dong, James Chih-Hsin Yang, Satoshi Oizumi, Koichi Goto, Manuel Cobo, Sang-We Kim, Te-Chun Hsia, Jarin Chindaprasirt, Fernanda Fujiki, Natalia Valdiviezo, Ignacio Casarini, Terufumi Kato, Xiangning Huang, Azura Evans, Elena Armenteros-Monterroso, Ana Bolanos, Suresh S. Ramalingam, Shun Lu
Institutions: Istanbul University-Cerrahpaşa, Samsung Medical Center, Wuhan Union Hospital, Union Hospital, National Taiwan University Hospital, National Hospital Organization Hokkaido Medical Center, Japan Cancer Society, National Cancer Center Hospital East, Hospital Regional Universitario de Málaga, Hospital Clínico Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Asan Medical Center, China Medical University, China Medical University Hospital, Khon Kaen University, Instituto do Câncer do Estado de São Paulo, Instituto Nacional de Enfermedades Neoplásicas, Centro Científico Tecnológico Mar del Plata, Kanagawa Prefectural Hospital Organization, AstraZeneca (Singapore), AstraZeneca (Spain), AstraZeneca (Canada), Emory University, Piedmont Cancer Institute, Shanghai Chest Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: AstraZeneca UK, AstraZeneca
OpenAlex ID: W7212049227
FWCI:
Cites:
Cited by:
Related to: